Recent Updates
Recently added Catalysts
TMDX Negative Sentiment Score: 20/100

TRANSMEDICS GROUP, INC. (NASDAQ: TMDX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds TransMedics Group, Inc. Investors of Upcoming Deadline

Key Takeaway: TransMedics Group, Inc. (NASDAQ: TMDX) is facing a class action lawsuit filed in the U.S. District Court for the District of Massachusetts. The lawsuit involves allegations of securities fraud, claiming that the company misrepresented its safety practices and engaged in fraudulent activities, including kickbacks and overbilling. Investors who purchased shares between February 28, 2023, and January 10, 2025, are urged to respond to the legal proceedings by the April 15, 2025 deadline for serving as lead plaintiff. The law firm Bernstein Liebhard LLP is representing the plaintiffs in this case.

Market Sentiment Analysis

CONCERNS & RISKS

  • TransMedics is facing a securities fraud class action lawsuit.
  • Allegations include misrepresentations about safety issues and unsafe practices.
  • The company is accused of using kickbacks and fraudulent overbilling.

Full Press Release Details

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of TransMedics Group, Inc. (NASDAQ: TMDX)?
Did you purchase your shares between February 28, 2023 and January 10, 2025, inclusive?
Did you lose money in your investment in TransMedics Group, Inc.?
Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
If you purchased or acquired TransMedics securities, and/or would like to discuss your legal rights and options please visit TransMedics Group, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of investors who purchased or acquired the securities of TransMedics between February 28, 2023 and January 10, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
According to the lawsuit, Defendants made misrepresentations concerning TransMedics’ engagement in unsafe practices, the hiding of safety issues and a lack of general safety oversight. In addition, the Company is alleged to have used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue.
If you wish to serve as lead plaintiff for the Class, you must file papers by April 15, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the TransMedics Group class action about?

The lawsuit involves allegations of securities fraud against TransMedics for misrepresentations and unsafe practices.

Who can participate in the TransMedics lawsuit?

Investors who purchased TransMedics shares between February 28, 2023, and January 10, 2025, may participate.

What is the deadline to file as lead plaintiff?

The deadline to file as lead plaintiff is April 15, 2025.

Are there any fees for participating in the lawsuit?

No, all representation is on a contingency fee basis with no fees or expenses for shareholders.

How can I contact Bernstein Liebhard LLP for more info?

You can contact Investor Relations Manager Peter Allocco at pallocco@bernlieb.com.

Last updated: Feb 25, 2025